A clinical-stage biotechnology company developing targeted cancer therapies based on the concept of synthetic lethality, aiming to selectively kill tumor cells while sparing normal tissue. Its research platform identifies genetic dependencies in cancer and advances small‑molecule drugs designed to e...
1 member of Congress has disclosed 1 trade in TNGO (TNGO), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2015-02-13 | Thomas R Tillis | sell | $1K – $15K |